Skip to main content
NVCR
NASDAQ Life Sciences

NovoCure's Optune Pax Wins CE Mark for Pancreatic Cancer, PANOVA-3 Data Shows Survival Benefit

Tom Rudovsky · Reported by Wiseek News
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$15.48
Mkt Cap
$1.793B
52W Low
$9.82
52W High
$18.92
52W Position info
58% above low
Off High info
18% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

NVCR sits 58% above its 52-week low of $9.82.

Summary

NovoCure's Optune Pax has received CE Mark approval for locally advanced pancreatic cancer, opening the European market for this indication. The approval is based on the PANOVA-3 trial, which showed a median overall survival benefit of 2.0 months (16.2 vs 14.2 months) in the ITT population. This positive regulatory development follows the company's recent announcement on June 18th of the Phase 3 TRIDENT trial failure for glioblastoma. The CE Mark and demonstrated survival benefit in pancreatic cancer represent a significant commercial opportunity and clinical validation for Optune Pax.

At the time of this announcement, NVCR was trading at $15.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $9.82 to $18.92. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

NVCR - Latest Insights

NVCR
Nov 09, 2026, 6:59 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.95
Real-time Price: $11.60 info
Change: -$2.35 (-17%) info
Market Cap: $1.354B info
NVCR
Oct 29, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.25
Real-time Price: $11.60 info
Change: -$2.65 (-19%) info
Market Cap: $1.354B info
NVCR
Oct 29, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $15.34
Real-time Price: $11.60 info
Change: -$3.74 (-24%) info
Market Cap: $1.354B info
NVCR
Oct 29, 2026, 6:59 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.25
Real-time Price: $11.60 info
Change: -$2.65 (-19%) info
Market Cap: $1.354B info
NVCR
Oct 01, 2026, 9:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $16.06
Real-time Price: $11.60 info
Change: -$4.46 (-28%) info
Market Cap: $1.354B info